CSL (ASX:CSL) share price lifts following new regulatory approval

CSL shares rise on vaccine win.

| More on:
a medical person in full protective gear with mask and gloves holds up a needle in one hand and a small bottle of vaccine in the other in a medical setting.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • The CSL share price is rising after getting regulatory approval
  • Younger children will now be able to get the improved flu vaccine
  • Plenty of analysts rate CSL as a buy, including Citi

The CSL Limited (ASX: CSL) share price is currently up by 3%. It has been reported that its new influenza vaccine has been approved by regulators for younger people.

CSL is one of the world's largest biotech businesses with a large vaccine division.

Latest win for CSL

The Australian has reported that the new generation of CSL's influenza vaccine has received regulatory approval.

This is the new type of cell-based influenza vaccine called Flucelvax Quad. According to CSL, this is significantly more effective than the protein-based vaccines that are grown in eggs and it can also be produced at a significant scale at shorter notice.

It was a year ago that CSL received approval for the vaccine's general use. The ASX healthcare share has sold over 100 million doses of it since the Therapeutic Goods Administration gave approval.

This vaccine has now been approved for children down to the age of 2 years old. It was reported by the newspaper that sales "are expected to soar".

This could be an important factor to reduce hospitalisations

The Australian quoted CSL's Jonathan Anderson, who is the head of medical affairs at Seqirus – the vaccine division of the ASX healthcare share.

With our healthcare system facing pressure from COVID-19 and influenza this winter, achieving high influenza vaccination coverage is crucial in ensuring we help to reduce the strain on hospitals.

This is even more important this year, and the expanded approval of Flucelvax Quad will be timely to give patients and health care professionals additional options.

The fact that much younger children are now eligible for this could be helpful because children that are under five are at more risk of severe flu, according to NSW Health.

Is the CSL share price an opportunity?

Since the start of 2022, the CSL share price has fallen by 13%.

During that time, the healthcare business has reported its FY22 half-year result. Whilst revenue increased 4%, net profit after tax (NPAT) fell by 5% in constant currency terms to $1.76 billion. The company said that there was a strong performance by the influenza vaccine business, Seqirus, which saw seasonal flu vaccine sales up 20%.

A new cell culture influenza vaccine facility has commenced construction in Australia.

CSL has received strong support from Vifor shareholders for the acquisition and plans to declare the offer successful. It said 74% of the shares have been tendered. The regulatory approval process for the acquisition is "on track" as well and management is confident that the remaining conditions will be satisfied.

Citi thinks that the CSL share price is a buy, with a price target of $335 – that's a potential upside of around 30%.

On Citi's numbers, the CSL share price is valued at 30x FY23's estimated earnings.

Motley Fool contributor Tristan Harrison has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns and has recommended CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Female pharmacist smiles with a digital tablet.
Healthcare Shares

Are Wesfarmers or Sigma shares a better buy in the pharmacy arena?

These two stocks are both leaders in the industry.

Read more »

A young man goes over his finances and investment portfolio at home.
Healthcare Shares

Down 20%, is the NIB share price undervalued?

Here's what Goldman Sachs is saying about this blue chip stock.

Read more »

four excited doctors with their hands in the air
Healthcare Shares

Sigma Healthcare shares rocket 39% on Chemist Warehouse merger approval

The ACCC doesn't believe the company's merger with Chemist Warehouse will lessen competition.

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

ASX 200 healthcare stock rockets on $75 million news

This marks another positive step for the company.

Read more »

Male doctor in a lab coat working at laptop looking serious.
Healthcare Shares

CSL shares are in the red for 2024. Are they a buy?

Meanwhile, the broader market has extended to new highs this year.

Read more »

A smiling businessman in the city looks at his phone and punches the air in celebration of good news.
Share Market News

Guess which ASX 300 stock is jumping 11% on big news

Big news is giving this stock an even bigger lift on Tuesday. What's happening?

Read more »

Two lab workers fist pump each other.
Healthcare Shares

Guess which ASX 200 healthcare stock is starting the week with a bang on big news!

What is getting investors excited today? Let's find out.

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

3 small-cap ASX healthcare shares 'with strong prospects'

Fund manager IML discusses why these 3 ASX healthcare shares are likely to rise in value.

Read more »